Shots:
- Exscientia to receive $20M as an option exercise fee and is eligible for development milestones along with royalties on any product sales
- BMS has elected to in-license an Exscientia’s immune-modulating drug candidate & will be responsible for clinical and commercial development of the product
- In May’21, the companies have expanded the collaboration to accelerate the discovery of drug candidates by using Exscientia’s AI technology for multiple therapeutic areas, including oncology and immunology
Click here to read full press release/ article | Ref: Exscientia | Image: Exscientia
The post BMS Exercises its Option to Develop Exscientia’s AI-Designed Drug Candidate first appeared on PharmaShots.
